Identification of CCR2 and CD180 as robust pharmacodynamic tumor and blood biomarkers for clinical use with BRD4/BET inhibitors

Clinical Cancer Research

Volumn 23, Issue 4, 2017, Pages 1025-1035

  Yeh, Tammie C ^a   O'Connor, Greg ^a   Petteruti, Philip ^a   Dulak, Austin ^a   Hattersley, Maureen ^a   Barrett, J Carl ^a   Chen, Huawei ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

6 (4 CHLOROPHENYL) N ETHYL 8 METHOXY 1 METHYL 4H [1,2,4]TRIAZOLO[4,3 A][1,4]BENZODIAZEPINE 4 ACETAMIDE; AZD 5153; BIRABRESIB; BROMODOMAIN INHIBITOR; CD180 ANTIGEN; CHEMOKINE RECEPTOR CCR2; LYMPHOCYTE ANTIGEN; MESSENGER RNA; TUMOR MARKER; UNCLASSIFIED DRUG; AZD5153; BRD4 PROTEIN, HUMAN; CCR2 PROTEIN, HUMAN; CD180 PROTEIN, HUMAN; FUSED HETEROCYCLIC RINGS; LEUKOCYTE ANTIGEN; MYC PROTEIN; MYC PROTEIN, HUMAN; NUCLEAR PROTEIN; PIPERAZINE DERIVATIVE; TRANSCRIPTION FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; FEMALE; HEMATOLOGIC MALIGNANCY; HEXIM1 GENE; HUMAN; HUMAN CELL; IN VIVO STUDY; INHIBITION KINETICS; NONHUMAN; ONCOGENE; ONCOGENE MYC; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RAT; RNA SEQUENCE; TRANSCRIPTOMICS; TUMOR XENOGRAFT; VOLUNTEER; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETICS; HEMATOLOGIC DISEASE; MOUSE; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; ANTIGENS, CD; BIOMARKERS, TUMOR; CELL LINE, TUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; HEMATOLOGIC NEOPLASMS; HETEROCYCLIC COMPOUNDS, 2-RING; HUMANS; MICE; NUCLEAR PROTEINS; PIPERAZINES; PROTO-ONCOGENE PROTEINS C-MYC; RATS; RECEPTORS, CCR2; TRANSCRIPTION FACTORS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 85012910498     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-16-1658     Document Type: Article

References (30)

1. Dhanak D, Jackson P. Development and classes of epigenetic drugs for cancer. Biochem Biophys Res Commun 2014;455:58-69.
2. Jung M, Gelato KA, Fernández-Montalvan A, Siegel S, Haendler B. Targeting BET bromodomains for cancer treatment. Epigenomics 2015;7:487-501.
3. Fu L, Tian M, Li X, Li J, Huang J, Ouyang L, et al. Inhibition of BET bromodomains as a therapeutic strategy for cancer drug discovery. Oncotarget 2015;6:5501-16.
4. Stathis A, Zucca E, Bekradda M, Gomez-Roca C, Delord J-P, de La Motte Rouge T, et al. Clinical Response of Carcinomas Harboring the BRD4-NUT Oncoprotein to the Targeted Bromodomain Inhibitor OTX015/MK-8628. Cancer Discov 2016;6:492-500.
5. Berthon C, Raffoux E, Thomas X, Vey N, Gomez-Roca C, Yee K, et al. Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study. Lancet Haematol 2016;3:e186-95.
6. Amorim S, Stathis A, Gleeson M, Iyengar S, Magarotto V, Leleu X, et al. Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study. Lancet Haematol 2016;3:e196-204.
7. O'Dwyer P, Piha-Paul S, French C, Harward S, Ferron-Brady G, Wu Y, et al. GSK525762, a selective bromodomain (BRD) and extra terminal protein (BET) inhibitor: results from part 1 of a phase I/II open-label single-agent study in patients with NUT midline carcinoma (NMC) and other cancers [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association of Cancer Research; 2016 Apr 16-20;New Orleans, LA. Abstr nr CT014.
8. Abramson J, Blum K, Flinn I, Gutierrez M, Goy A, Maris M, et al. BET inhibitor CPI-0610 is well tolerated and induces responses in diffuse large B-cell lymphoma and follicular lymphoma: preliminary analysis of an ongoing phase I study [abstract]. In: Proceedings from the 57th Annual Meeting of the American Society of Hematology; 2015 Dec 5-8; Orlando, FL. Abstr nr1491.
9. Shapiro G, Dowlati A, LoRusso P, Eder J, Anderson A, Do K, et al. Clinically efficacy of the BET bromodomain inhibitor TEN-010 in an open-label substudy with patients with documented NUT-midline carcinoma (NMC) [abstract]. In: Proceedings of the 27th AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2015 Nov 5-9; Boston, MA. Abstr nr A49.
10. Bradbury RH, Callis R, Carr GR, Chen H, Clark E, Feron L, et al. Triazolopyridazine-based bromodomain and extraterminal inhibitors: the discovery of (3R)-4-[2-[4-[1-(3-methoxy-[1,2,4]triazolo[4,3-b]pyr-idazin-6-yl)-4-piperidyl]phenoxy]ethyl]-1,3-dimethyl-piperazin-2-one (AZD5153). J Med Chem 2016;59:7801-17.
11. Hattersley M, Rhyasen G, Yao Y, Dulak A, Wang W, Petteruti P, et al. Therapeutic activity of bivalent BRD4 inhibitor AZD5153 in hematological cancers [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA Abstr nr 4705.
12. Rhyasen G, Yao Y, Dulak A, Castriotta L, Jacques K, Hattersley M, et al. BRD4 amplification facilitates an oncogenic gene expression program in high-grade serous ovarian cancer [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA Abstr nr 1971.
13. Rhyasen G, Hattersley M, Yao Y, Dulak A, Wang W, Petteruti P, et al. et al. AZD5153: a novel bivalent BET bromodomain inhibitor highly active against hematologic malignancies. Mol Cancer Ther 2016 Aug 29. pii: molcanther.0141.2016. [Epub ahead of print].
14. Mertz JA, Conery AR, Bryant BM, Sandy P, Balasubramanian S, Mele DA, et al. Targeting MYC dependence in cancer by inhibiting BET bromodomains. Proc Natl Acad Sci U S A 2011;108:16669-74.
15. Coude M-M, Braun T, Berrou J, Dupont M, Bertrand S, Masse A, et al. BET inhibitor OTX015 targets BRD2 and BRD4 and decreases c-MYC in acute leukemia cells. Oncotarget 2015;6:17698-712.
16. Zuber J, Shi J, Wang E, Rappaport AR, Herrmann H, Sison EA, et al. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature 2011;478:524-8.
17. Loven J, Hoke HA, Lin CY, Lau A, Orlando DA, Vakoc CR, et al. Selective inhibition of tumor oncogenes by disruption of super-enhancers. Cell 2013;153:320-34.
18. Sengupta D, Kannan A, Kern M, Moreno MA, Vural E, Stack B, et al. Disruption of BRD4 at H3K27Ac-enriched enhancer region correlates with decreased c-Myc expression in Merkel cell carcinoma. Epigenetics 2015;10:460-6.
19. Devaraj SGT, Fiskus W, Shah B, Qi J, Sun B, Iyer SP, et al. HEXIM1 induction is mechanistically involved in mediating anti-AML activity of BET protein bromodomain antagonist. Leukemia 2016;30:504-8.
20. Chen R, Yik JHN, Lew QJ, Chao S-H. Brd4 and HEXIM1: multiple roles in P-TEFb regulation and cancer. Biomed Res Int 2014;2014:232870.
21. Gilham D, Wasiak S, Tsujikawa LM, Halliday C, Norek K, Patel RG, et al. RVX-208, a BET-inhibitor for treating atherosclerotic cardiovascular disease, raises ApoA-I/HDL and represses pathways that contribute to cardiovascular disease. Atherosclerosis 2016;247:48-57.
22. Nicholls SJ, Gordon A, Johansson J, Wolski K, Ballantyne CM, Kastelein JJP, et al. Efficacy and safety of a novel oral inducer of apolipoprotein a-I synthesis in statin-treated patients with stable coronary artery disease a randomized controlled trial. J Am Coll Cardiol 2011;57:1111-9.
23. Waring MJ, Chen H, Rabow AA, Walker G, Bobby R, Boiko S, et al. Potent and selective bivalent inhibitors of BET bromodomains. Nat Chem Biol 2016, in press.
24. Chan CH, Fang C, Qiao Y, Yarilina A, Prinjha RK, Ivashkiv LB. BET bromodomain inhibition suppresses transcriptional responses to cytokine-Jak-STAT signaling in a gene-specific manner in human monocytes. Eur J Immunol 2015;45:287-97.
25. + T-cell cytokine production and autoimmunity by BET protein and c-Myc inhibitors. Proc Natl Acad Sci U S A 2012;109:14532-7.
26. Xiao Y, Liang L, Huang M, Qiu Q, Zeng S, Shi M, et al. Bromodomain and extra-terminal domain bromodomain inhibition prevents synovial inflammation via blocking IκB kinase-dependent NF-κB activation in rheumatoid fibroblast-like synoviocytes. Rheumatology 2016;55:173-84.
27. Belkina AC, Nikolajczyk BS, Denis GV. BET protein function is required for inflammation: Brd2 genetic disruption and BET inhibitor JQ1 impair mouse macrophage inflammatory responses. J Immunol 2013;190:3670-8.
28. O'Connor T, Borsig L, Heikenwalder M. CCL2-CCR2 signaling in disease pathogenesis. Endocr Metab Immune Disord Drug Targets 2015;15:105-18.
29. Lim SY, Yuzhalin AE, Gordon-Weeks AN, Muschel RJ. Targeting the CCL2-CCR2 signaling axis in cancer metastasis. Oncotarget 2016;7:28697-710.
30. Schultz TE, Blumenthal A. The RP105/MD-1 complex: molecular signaling mechanisms and pathophysiological implications. J Leukoc Biol 2016 Apr 11. pii: jlb.2VMR1215-582R [Epub ahead of print].